BeOne Medicines (NASDAQ:ONC) Given New $454.00 Price Target at TD Cowen

BeOne Medicines (NASDAQ:ONC) had its price objective boosted by analysts at TD Cowen from $424.00 to $454.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price objective points to a potential upside of 37.87% from the stock’s current price.

Several other equities research analysts have also issued reports on ONC. Morgan Stanley reissued an “overweight” rating on shares of BeOne Medicines in a research note on Thursday. JPMorgan Chase & Co. upped their price target on BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Barclays increased their price target on BeOne Medicines from $403.00 to $407.00 and gave the stock an “overweight” rating in a research report on Thursday. Leerink Partners raised their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Finally, Wells Fargo & Company began coverage on BeOne Medicines in a research report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $400.00.

BeOne Medicines Stock Performance

Shares of NASDAQ:ONC traded up $1.77 during trading on Thursday, hitting $329.30. 186,427 shares of the stock traded hands, compared to its average volume of 280,046. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The company has a fifty day moving average price of $294.53 and a two-hundred day moving average price of $308.67. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $385.22. The company has a market cap of $36.13 billion, a price-to-earnings ratio of 73.51 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, equities analysts predict that BeOne Medicines will post 5.93 EPS for the current year.

Insider Transactions at BeOne Medicines

In related news, CEO John Oyler sold 145,861 shares of BeOne Medicines stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the sale, the chief executive officer directly owned 8,122 shares in the company, valued at approximately $2,484,925.90. The trade was a 94.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,484 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $269.37, for a total value of $399,745.08. Following the sale, the chief operating officer owned 40 shares of the company’s stock, valued at approximately $10,774.80. This trade represents a 97.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 345,561 shares of company stock worth $105,625,947 over the last ninety days. 6.19% of the stock is currently owned by corporate insiders.

Institutional Trading of BeOne Medicines

Several large investors have recently made changes to their positions in ONC. EFG International AG acquired a new position in BeOne Medicines in the 4th quarter valued at $25,000. Leonteq Securities AG acquired a new stake in BeOne Medicines during the 4th quarter worth $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines during the 2nd quarter worth $35,000. CWM LLC grew its holdings in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new stake in BeOne Medicines during the 4th quarter valued at about $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings beat estimates: BeOne reported earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat supports the view that the company’s oncology portfolio is delivering stronger profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year revenue of $6.6 billion to $6.8 billion, above Wall Street’s $6.5 billion forecast. Reports also indicated that second-quarter revenue surged 30%, reinforcing expectations for continued commercial momentum. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analysts raised targets and maintained bullish ratings: Guggenheim raised its target to $430 and Truist lifted its target to $418, both with Buy ratings. Citizens JMP raised its target to $405 with a Market Outperform rating. RBC trimmed its target slightly to $450 but retained an Outperform rating. These targets imply substantial upside from recent trading levels. Analyst rating updates
• Positive Sentiment: Pipeline progress: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially supporting faster regulatory engagement and development. UK Innovation Passport announcement
• Neutral Sentiment: Insider sale appears administrative: CFO Aaron Rosenberg sold 1,157 shares worth approximately $362,000 to cover tax withholding related to vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.